Guidelines for mono, double and triple antithrombotic therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33441477.
- Also identified by DOI 10.1136/postgradmedj-2020-138938.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Guidelines for antithrombotic therapy are complex, especially if a patient has several indications that require antithrombotic therapy. In general, no patient should receive lifelong double or triple antithrombotic therapy. In this overview, we outline the most common indications for mono, double and triple antithrombotic therapy; the preferred antithrombotic therapy and the recommended duration of therapy. Both antiplatelet therapy and therapeutic anticoagulation therapy with vitamin K antagonists or direct oral anticoagulants were included. European guidelines were used or, if no European guidelines were available, the Dutch guidelines were used.
Medical subject headings
- Anticoagulants
- Atrial Fibrillation
- Coronary Artery Disease
- Fibrinolytic Agents
- Practice Guidelines as Topic
- Thromboembolism
- Vitamin K